

Press Release

11 January 2022 08:45:00 CET

IndiTreat® to be distributed in Czech Republic and Slovakia through Promedica

2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, announced today that Promedica Prague Group, the largest independent healthcare distributor in the Czech Republic, will bring IndiTreat® products to Czech and Slovakian patients and professionals. This new collaboration agreement brings the total of 2cureX partners to 9, covering 14 European countries and a combined population of 235 million people.

2cureX and Promedica Prague Group have signed an agreement by which Promedica Prague Group becomes the distributor of IndiTreat® products in Czech Republic and Slovakia. Under the terms of the collaboration, Promedica Prague Group will promote IndiTreat® to oncology professionals, sign supply agreements with hospitals and manage the sample logistics between the hospitals and 2cureX labs in Copenhagen.

IndiTreat® present in 14 countries

“Promedica Prague Group is the largest independent healthcare distributor in the Czech Republic, also covering Slovakia, and we are thrilled to welcome them as a 2cureX partner. With this agreement, IndiTreat® is distributed in 14 European countries already”, said **Fernando Andreu, CEO of 2cureX**. “This is outstanding, considering that back in September last year we were present in 6 countries only. The fast expansion reflects the interest our tests are generating in the market”.

“Adding IndiTreat® to our Diagnostics and Pharma product offering will give our sales team yet another very strong and innovative solution for patients and their doctors. As a market leader, it is important that we constantly offer leading edge health solutions” said **Hanuš Pavel, CEO Promedica Prague Group**.

Czech Republic and Slovakia – two important countries in the center of Europe.

“Czech Republic and Slovakia are two important countries to cover the Central European cancer IVD space, and with the health professionals network of Promedica Prague Group I am very confident that we have found the best partner”, said **Jesper Floyd Kristiansen, VP Business Development at 2cureX**. “This agreement gives us access to a population of 16 million people, with approximately 12,000 new cases of colorectal cancer every year. We expect IndiTreat® to make a difference for many of these patients going forward”.

The agreement has been signed for an initial term of three years, with automatic renewal for successive terms. Other terms of the agreement have not been disclosed. Sales impact of this agreement is expected to show in 2022.

For more information about 2cureX:

Fernando Andreu, Chief Executive Officer

E-mail: fa@2curex.com

Telephone: +45 2279 5399

www.2curex.com

About Promedica Prague Group

Promedica Prague Group is the biggest independent healthcare distributor in the Czech Republic with more than 220 employees and since 2017 also covering Slovakia.

The distribution is based on a strong sales team divided in 16 divisions according to specializations and consists of more than 70 experts – company representatives. Our sales representatives are always perfectly familiar with our products and know what's going on in healthcare – they are equal partners for healthcare workers and help spreading new findings and know-how of leading producers worldwide.

About 2cureX

2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient's tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.

The first two IndiTreat® tests are aimed at optimizing treatment decisions in patients with metastatic colorectal cancer (IndiTreat® Start for first line of therapy, IndiTreat® Extend for third line). Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.

According to several reports, the total yearly expenditure in cancer-related *In Vitro Diagnostic* (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com

Certified Adviser: Redeye AB, +46 8 121 576 90, certifiedadviser@redeye.se

This information is information that 2cureX is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-01-11 08:45 CET.

Attachments

IndiTreat® to be distributed in Czech Republic and Slovakia through Promedica